NASDAQ · Biotechnology

TScan Therapeutics, Inc. (TCRX) Stock

$0.23 -17.59% NASDAQ: TCRX Healthcare

Valuation

MetricValue
Price$0.23
Market Cap$13.94M
P/E Ratio-0.35
P/B Ratio0.60
P/S Ratio2.75
EPS (TTM)$-1.00
52-Week High$2.57
52-Week Low$0.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-108.72%
ROA-68.66%
ROCE-85.80%
Gross Margin-1360.00%
Operating Margin-1360.00%
Net Margin-13.61%
Debt/Equity1.32
Current Ratio8.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$10.0M$14.0M$21.0M$3.0M$10.0M
Operating Profit$-49.0M$-67.0M$-93.0M$-135.0M$-136.0M
Net Profit$-49.0M$-66.0M$-89.0M$-127.0M$-130.0M
EPS$-2.03$-2.74$-1.36$-1.14$-1.00
Op Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$188.0M$199.0M$272.0M$371.0M$229.0M
Total Liabilities$27.0M$100.0M$121.0M$130.0M$106.0M
Cash$161.0M$120.0M$133.0M$179.0M$152.0M
Borrowings$6.0M$86.0M$92.0M$97.0M$94.0M

Latest News

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 24, 2026 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT Newswires · Jun 22, 2026 TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation GlobeNewswire · Jun 22, 2026 Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies Business Wire · Jun 3, 2026 TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss Insider Monkey · Jun 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-49.0M$-67.0M$-61.0M$-111.0M$-135.0M
Investing Cash Flow$-20.0M$-8.0M$-64.0M$-56.0M$105.0M
Financing Cash Flow$0$0$93.0M$160.0M$-1.0M
Net Cash Flow$131.0M$-41.0M$13.0M$45.0M$-26.0M
Free Cash Flow$-59.0M$-71.0M$-65.0M$-115.0M$-140.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.09
FCF Yield-605.07%
Quick Ratio3.37
Interest Coverage-43.22
Return 1Y-48.02%
Return 3Y-56.40%
Return 5Y-91.24%

Ownership

Insiders Held0.20%
Institutions Held59.46%
Institutions Float Held59.58%
Institutional HolderSharesReport Date
Lynx1 Capital Management Lp8,019,1482026-03-31
BVF Inc.5,564,2902026-03-31
Baker Bros. Advisors, LP2,784,7922026-03-31
Vanguard Capital Management LLC2,154,2562026-03-31
Blackrock Inc.1,840,9522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACETAdicet Bio, Inc. $5.74 -7.12% -0.57 $53.66M 0.00%
ACRVAcrivon Therapeutics, Inc. $1.87 -0.53% -1.12 $80.04M 0.00%
FBIOFortress Biotech, Inc. $2.09 +2.45% 0.64 $69.43M 0.00%
IMUXImmunic, Inc. $7.56 -0.92% -1.59 $102.98M 0.00%
LITSLite Strategy, Inc. $1.22 -3.94% -0.15 $41.51M 0.00%

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc. is led by CEO Gavin MacBeath, employs 200 people, headquartered in US, publicly traded since 2021.

TScan Therapeutics, Inc. (TCRX) stock trades at $0.23 with a market capitalization of $13.94M. The stock is valued at a price-to-earnings (P/E) ratio of -0.35, price-to-book of 0.60, price-to-sales of 2.75. Over the past 52 weeks the stock has ranged between $0.23 and $2.57, and currently trades 91.1% below its 52-week high.

On profitability, TScan Therapeutics, Inc. generates a return on equity (ROE) of -108.72%, return on capital employed of -85.80%, an operating margin of -1360.00%, a net profit margin of -13.61%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1167.49 -0.18% JNJ Johnson & Johnson $258.43 +0.76% ABBV AbbVie Inc. $274.80 +0.87% MRK Merck & Company, Inc. Common Stock (new) $144.19 +1.27% UNH UnitedHealth Group Incorporated Common Stock (DE) $383.12 +3.28% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $656.23 +0.65% AMGN Amgen Inc. $410.26 +0.69% GILD Gilead Sciences, Inc. $149.11 +1.37% ABT Abbott Laboratories $100.17 +1.71% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides